Zentalis Pharmaceuticals, Inc. Common Stock (ZNTL)
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancers with high unmet medical needs. The company's approach involves designing small molecule therapeutics that inhibit cancer-driving proteins, with a focus on oncology indications such as solid tumors and hematologic malignancies.
Company News
Zentalis Pharmaceuticals granted non-qualified stock options to purchase 381,000 shares of common stock to six newly hired employees under their 2022 Employment Inducement Incentive Award Plan.
Zentalis Pharmaceuticals reported a narrower net loss in Q2 2025, reducing operating expenses by 44.7% while maintaining cash reserves to support operations through late 2027. The company continues developing azenosertib, a cancer therapy, with ongoing clinical trials for platinum-resistant ovarian cancer.
Stay up to date with the latest financial news! Listen to the Wall Street Breakfast podcast on Seeking Alpha, iTunes, and Spotify.
Intra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight following pipeline and regulatory updates, respectively.
Zentalis Pharma (NASDAQ:ZNTL) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 3 0 0 0 Last 30D 2 1 0 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 1 2 0 0 0 These 6 analysts have an average price target of $43.83 versus the current...